more_reports

PDUFA Date Nearing for New PSVT Drug

Research Report
  ()
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons

  ()
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.
Tags: Biotechnology / Pharmaceuticals

Two Use Cases for AI in Healthcare

  ()
In both, proprietary software platforms analyze heaps of data, but one focuses on genetics, the other neurology. Learn more about the companies behind the technology.
Tags: TechnologyLife Sciences Tools & Diagnostics

Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients

Research Report
  ()
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Stock Looks Like Is Has a Great Set Up

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy.
Tags: Biotechnology / Pharmaceuticals

Biotech Advancing Pivotal Phase III Breast Cancer Trial

Research Report
  ()
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc.
Tags: Biotechnology / Pharmaceuticals

AI Study Tracks Unexpected Cognitive Gains in Vascular Dementia Trial

  ()
Hemostemix Inc.'s (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) Phase 1 trial, in collaboration with Firefly Neuroscience Inc. (AIFF:NASDAQ), is evaluating ACP-01s impact on vascular dementia using AI-driven brain analysis. Early insights could reshape treatment approaches.
Tags: Healthcare Services

New Drug for Major Depressive Disorder Gets Good Surprise

Research Report
  ()
When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

With Competitor Out, New Drug Gains Edge in Chronic Cough

Research Report
  ()
Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

FDA OKs Trial of Cell Reservoir in Thyroid Disease

Research Report
  ()
In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report.
Tags: Medical Devices

Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock.
Tags: Biotechnology / Pharmaceuticals

Canadian Healthcare Co. Showcases Stable FQ424

Research Report
  ()
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data

  ()
Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next.
Tags: Biotechnology / Pharmaceuticals

Virtual Healthcare Breakthrough Expanding Access for 6.9M Medicaid Patients in New York

  ()
Rocket Doctor, under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), is now an in-network provider for New York Medicaid, expanding virtual healthcare access to 6.9 million beneficiaries. Find out how this milestone offers the possibility to reshape healthcare accessibility.
Tags: Healthcare Services

DMT Study Set To Explore Breakthrough Potential in Stroke Recovery

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.
Tags: Biotechnology / Pharmaceuticals

Healthcare Tech Co. To Acquire Digital Health Platform

  ()
This will expand its ecosystem of AI-powered products. Read on to learn more about its offerings and rapidly growing sector.
Tags: Healthcare Services

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

New Strategic Moves Aim To Accelerate Growth in AI Healthcare

  ()
Light AI Inc. (ALGO:CBOE) announces major marketing campaigns, advisory board appointments, and a key regulatory partnership to drive growth. Discover how these strategic moves could shape the future of AI healthcare.
Tags: Healthcare ServicesTechnology

Kentucky Medical Co. Has Strong Operating Fundamentals

Research Report
  ()
Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note.
Tags: Healthcare ServicesMedical Devices

AI Stock in an Uptrend That Is Likely To Continue

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Light AI Inc. (ALGO:CBOE) is an Immediate Strong Buy.
Tags: Medical DevicesLife Sciences Tools & Diagnostics

Biotech Requests OK to Assess Device in Second Indication

Research Report
  ()
The company behind this possible "pipeline in a device" wants to evaluate it now in thyroid disease after having begun with trials in type 1 diabetes, noted an H.C. Wainwright & Co. report.
Tags: Medical Devices

Healthcare Pioneer Expands Revolutionary Treatment Platform

  ()
Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Cell Pouch technology. One analyst says it is the "most advanced encapsulation device in development."
Tags: Biotechnology / PharmaceuticalsMedical Devices